Immunitybio Inc (IBRX)

NASDAQ
Currency in USD
3.23
+0.06(+1.74%)
Real-time Data
IBRX Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
3.073.28
52 wk Range
2.2810.53
Key Statistics
Edit
Prev. Close
3.17
Open
3.07
Day's Range
3.07-3.28
52 wk Range
2.28-10.53
Volume
2.3M
Average Vol. (3m)
5.88M
1-Year Change
-33.12%
Book Value / Share
-1.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
12.19
Upside
+277.32%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Immunitybio Inc Company Profile

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Compare IBRX to Peers and Sector

Metrics to compare
IBRX
Peers
Sector
Relationship
P/E Ratio
−4.0x−4.0x−0.6x
PEG Ratio
−0.26−0.190.00
Price / Book
−3.1x1.9x2.6x
Price / LTM Sales
318.7x72.6x3.1x
Upside (Analyst Target)
120.8%293.3%52.8%
Fair Value Upside
Unlock28.9%8.4%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.19
(+277.32% Upside)

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
-0.14 / -0.18
Revenue / Forecast
6.10M / 2.93M
EPS Revisions
Last 90 days

People Also Watch

2.670
RR
-1.48%
2.96
RZLV
-2.89%
7.609
APLD
+0.25%
72.83
TEM
+2.28%
11.660
RGTI
+5.81%

FAQ

What Is the Immunitybio Inc (IBRX) Stock Price Today?

The Immunitybio Inc stock price today is 3.23

What Stock Exchange Does Immunitybio Inc Trade On?

Immunitybio Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Immunitybio Inc?

The stock symbol for Immunitybio Inc is "IBRX."

What Is the Immunitybio Inc Market Cap?

As of today, Immunitybio Inc market cap is 2.36B.

What is Immunitybio Inc Earnings Per Share?

The Immunitybio Inc EPS is -0.863.

What Is the Next Immunitybio Inc Earnings Date?

Immunitybio Inc will release its next earnings report on Mar 04, 2025.

From a Technical Analysis Perspective, Is IBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.